BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11694436)

  • 1. New contrast agents for imaging the liver.
    Helmberger T; Semelka RC
    Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):745-66, vi. PubMed ID: 11694436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of hepatocyte-specific contrast agents in hepatobiliary magnetic resonance imaging.
    Burke C; Alexander Grant L; Goh V; Griffin N
    Semin Ultrasound CT MR; 2013 Feb; 34(1):44-53. PubMed ID: 23395317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree.
    Seale MK; Catalano OA; Saini S; Hahn PF; Sahani DV
    Radiographics; 2009 Oct; 29(6):1725-48. PubMed ID: 19959518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Status and development of new clinical contrast media for MR diagnosis of liver diseases].
    Rummeny EJ; Peters PE
    Radiologe; 1992 May; 32(5):225-31. PubMed ID: 1635982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Magnetic resonance imaging of the liver: what kind of contrast agents?].
    De Gaspari A; De Cobelli F; Del Maschio A
    Radiol Med; 2001 Sep; 102(3):109-21. PubMed ID: 11677451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Magnetic resonance tomography of the hepatobiliary system: indications, limitations and outlook].
    Vogl TJ; Hammerstingl R; Schnell B; Eibl-Eibesfeldt B; Peqios W; Lissner J
    Bildgebung; 1992 Dec; 59(4):195-9. PubMed ID: 1292771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatobiliary enhancement with Gd-EOB-DTPA: comparison of spin-echo and STIR imaging for detection of experimental liver metastases.
    Mühler A; Clément O; Vexler V; Berthezène Y; Rosenau W; Brasch RC
    Radiology; 1992 Jul; 184(1):207-13. PubMed ID: 1609081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contrast-enhanced MR imaging of the pancreas.
    Kettritz U; Semelka RC
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):87-100. PubMed ID: 8673719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocyte-specific magnetic resonance imaging contrast agents.
    Fidler J; Hough D
    Hepatology; 2011 Feb; 53(2):678-82. PubMed ID: 21274888
    [No Abstract]   [Full Text] [Related]  

  • 10. Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg).
    Giovagnoni A; Paci E
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):61-72. PubMed ID: 8673717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of action of liver contrast agents: impact for clinical use.
    Clément O; Siauve N; Cuénod CA; Vuillemin-Bodaghi V; Leconte I; Frija G
    J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S45-52. PubMed ID: 10608397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.
    Reimer P; Schneider G; Schima W
    Eur Radiol; 2004 Apr; 14(4):559-78. PubMed ID: 14986050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contrast-enhanced MR imaging of the liver.
    Saini S
    Radiology; 1992 Jan; 182(1):12-4. PubMed ID: 1727273
    [No Abstract]   [Full Text] [Related]  

  • 14. MultiHance: help or hype?
    Bartolozzi C; Spinazzi A
    J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S151-9. PubMed ID: 10608411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble-type hepatobiliary contrast agents for MR imaging.
    de Haën C; Gozzini L
    J Magn Reson Imaging; 1993; 3(1):179-86. PubMed ID: 8428085
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical hepatic imaging with paramagnetic positive enhancers.
    Bernardino ME
    Magn Reson Med; 1991 Dec; 22(2):334-8; discussion 343-6. PubMed ID: 1812367
    [No Abstract]   [Full Text] [Related]  

  • 17. Gadoxetic acid-enhanced hepatobiliary phase MR imaging: cellular insight.
    Pastor CM
    Radiology; 2010 Nov; 257(2):589. PubMed ID: 20959554
    [No Abstract]   [Full Text] [Related]  

  • 18. Liver lesion characterization: the wrong choice of contrast agent can mislead the diagnosis of hemangioma.
    Pradella S; Lucarini S; Colagrande S
    AJR Am J Roentgenol; 2012 Nov; 199(5):W662. PubMed ID: 23096214
    [No Abstract]   [Full Text] [Related]  

  • 19. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
    Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
    J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic resonance imaging of focal liver lesions: approach to imaging diagnosis.
    Fowler KJ; Brown JJ; Narra VR
    Hepatology; 2011 Dec; 54(6):2227-37. PubMed ID: 21932400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.